Market Research Report · 2020–2040 · Base Year 2025
Global Topical Flowable and Powder Hemostats Market
Value (2025)
USD 2,958.89 Mn
Forecast (2040)
USD 7,577.70 Mn
Global Market Trajectory (USD Million)
The market is projected to expand roughly 2.56× over the forecast horizon, growing at a 6.47% CAGR between 2025 and 2040.
Market Definition
The topical flowable and powder hemostats market covers absorbable and biologically active agents applied directly at the surgical site to control bleeding that conventional techniques cannot easily manage. Topical haemostatic agents serve as adjuncts to electrosurgical coagulation and suture ligation, and are especially valuable where suturing or cautery would be ineffective or hazardous — such as raw-surface bleeding from the cut edge of bone, solid organs or soft tissue, or bleeding near delicate structures at risk of damage. [British Journal of Surgery, 2023] Clinical references generally group these agents into mechanical, active, flowable and fibrin-sealant categories. [U.S. Pharmacist]
Flowable Hemostats
Thick, spreadable gelatin-matrix formulations (often combined with thrombin) that conform to irregular wound surfaces and reach difficult, wet or deep-seated bleeding sites that are hard to access with other methods.
[U.S. Pharmacist]
Hemostatic Powders
Polysaccharide, oxidized-regenerated-cellulose or gelatin-based powders applied dry or sprayed over broad, irregular surfaces; they absorb water to concentrate platelets and clotting factors and accelerate clot formation, making them well suited to laparoscopic and endoscopic procedures.
[Aegis Lifesciences]
Because these products are absorbable and typically require no removal, they help avoid clot disruption and re-bleeding, and are naturally resorbed by the body over time. [Aegis Lifesciences] Effective hemostasis is clinically critical across specialties — in spine surgery, for example, uncontrolled bleeding carries the risk of spinal-cord compression and central-nervous-system damage, so hemostatic agents are an important adjunct to bleeding control. [Hemostats in Spine Surgery, Expert Panel Review] Collectively, the market spans these flowable matrices and hemostatic powders and their use across general, cardiovascular, orthopedic, neurological, gynecological and other surgical fields.
Product Summary — Impact on Market
The competitive core of the topical flowable and powder hemostats market is defined by a small group of flagship product families. The launches and portfolio moves below are the principal commercial catalysts shaping segment growth, pricing, and adoption across hospitals and ambulatory surgical centers.
Baxter International Inc. — Hemostats & Sealants Portfolio
FLOSEAL Hemostatic Matrix
A gelatin–thrombin flowable matrix that conforms to irregular wound surfaces and reaches difficult-access bleeding sites. As one of the category-defining active flowable hemostats, it anchors Baxter's leadership in the gelatin–thrombin combination segment across cardiovascular, spine and general surgery.
PERCLOT Absorbable Hemostatic Powder
A passive, plant-starch polysaccharide powder that is ready-to-use for patients with intact coagulation. Its U.S. introduction marked Baxter's first passive hemostat in the market, broadening the portfolio to a full active-plus-passive range and expanding the addressable powder segment.
HEMOPATCH Sealing Hemostat (Room-Temperature)
An NHS-PEG absorbable collagen pad for tissue sealing, dura sealing and hemostasis. The room-temperature reformulation removes cold-chain requirements and extends shelf life, improving accessibility in high-turnover operating rooms and ambulatory settings.
Ethicon, Inc. / Johnson & Johnson MedTech — Biosurgery Portfolio
SURGICEL Powder Absorbable Hemostat
An oxidized regenerated cellulose (ORC) powder that can be applied across broad or irregular wound surfaces. As part of the long-established SURGICEL brand, it reinforces Ethicon's leadership in the ORC-based hemostat category and its wide surgical-specialty footprint.
ETHIZIA Hemostatic Sealing Patch
A synthetic-polymer sealing patch (developed on GATT Technologies chemistry) designed to be equally active on both sides. In clinical study it stopped bleeding within 30 seconds in 80% of patients, positioning it as a differentiated competitor to fibrin-sealant patches for difficult-to-control disruptive bleeding.
Recent Developments
Jul 2021
Baxter announced the acquisition of the
PerClot Polysaccharide Hemostatic System to expand its Advanced Surgery portfolio, adding a passive absorbable powder platform.
[Business Wire]
Jul 2023
Baxter launched
PERCLOT Absorbable Hemostatic Powder in the U.S. — its first passive hemostat in that market — completing a full active-plus-passive bleeding-control range.
[Baxter]
Nov 2023
Ethicon introduced the
ETHIZIA Hemostatic Sealing Patch (CE Mark), a synthetic-polymer patch clinically proven to stop disruptive bleeding, with a phased EMEA and global rollout.
[J&J]
Apr 2025
Baxter launched a new
room-temperature Hemopatch Sealing Hemostat in Europe, eliminating refrigeration and enabling rapid, convenient application during surgery.
[Baxter]
2025
Baxter's
room-temperature Hemopatch Sealing Hemostat gained commercial momentum in Australia and New Zealand, extending its reach in the Asia-Pacific region.
[PR Newswire]
Launch
Ethicon launched a
new absorbable adjunctive hemostat, further broadening its Biosurgery portfolio for intraoperative bleeding control.
[BioSpectrum Asia]
Launch
Ethicon launched a
hemostatic patch impregnated with Fibroline solutions, applying advanced dry-impregnation technology to hemostatic patch design.
[Techtera]
Report Description
The Global Topical Flowable and Powder Hemostats Market was valued at approximately USD 2,958.89 million in 2025 and is projected to reach approximately USD 7,577.70 million by 2040, growing at a CAGR of 6.47% from 2025 to 2040. The study considers 2025 as the base year, with a forecast period of 2026 to 2040, and analyzes and forecasts the market in terms of value (USD Million).
The market covers the development, manufacturing and distribution of topical hemostatic products used to control and manage bleeding during surgical procedures. Flowable hemostats are injectable or spreadable formulations that conform to irregular wound surfaces and reach bleeding sites that are difficult to access, while powder hemostats are finely processed materials applied directly to bleeding tissue to promote clot formation. These products may contain absorbable materials such as gelatin, oxidized regenerated cellulose, collagen or other hemostatic agents, and are used across general surgery, cardiovascular surgery, orthopedic surgery, neurosurgery, trauma care and other specialties.
Rapid, localized bleeding control
Flowable formulations conform to uneven anatomy and reach difficult sites; powders spread over broad or irregular wounds — useful where suturing, ligation, cautery or compression is insufficient.
Versatile, easy application
Applied directly to tissue without complex technique; many absorbable formulations break down after achieving hemostasis, reducing removal, blood loss and transfusion needs.
Technology-driven innovation
Advances in bioactive materials, delivery systems, particle formulations and combination technologies deliver faster clotting, better adherence and predictable absorption.
Growth is supported by increasing surgical volumes, the rising prevalence of chronic diseases requiring intervention, and the growing adoption of minimally invasive and complex procedures. The expansion of hospitals, ambulatory surgical centers, trauma-care facilities and advanced surgical services further reinforces demand. As procedures grow more complex and providers prioritize efficient bleeding management, the market is expected to see sustained growth driven by rising surgical demand, product innovation and increasing adoption of advanced topical hemostatic solutions.
Market Dynamics
Drivers
Rising surgical volumes, growth in minimally invasive and complex procedures, and expansion of ASCs and trauma-care networks.
Restraints
High product cost, stringent regulatory and biocompatibility requirements, and reimbursement variability across regions.
Opportunities
Room-temperature and ready-to-use formats, synthetic and combination technologies, and expansion into emerging APAC and LATAM markets.
Challenges
Competition from conventional bleeding-control techniques and the need to demonstrate clear clinical and economic value.
Market Segmentation
The market is segmented by product type, material/composition, surgical application, end user and region.
By Product Type
Flowable Hemostats
Gelatin–Thrombin Flowable Hemostatic Matrix Gelatin-Based Flowable Matrix Without Thrombin Collagen-Based Flowable Hemostats Other Flowable Hemostats
Hemostatic Powders
Microporous Polysaccharide Hemostatic Powder Oxidized Regenerated Cellulose (ORC) Hemostatic Powder Gelatin-Based Hemostatic Powder Chitosan-Based Hemostatic Powder Collagen-Based Hemostatic Powder Other Hemostatic Powders
By Material / Composition
Gelatin-Based Polysaccharide-Based Oxidized Regenerated Cellulose-Based Chitosan-Based Collagen-Based Combination / Thrombin-Containing Other Materials / Compositions
By Surgical Application
General & Abdominal Surgery Cardiovascular Surgery Orthopedic & Spine Surgery Gynecological Surgery Urological Surgery ENT & Sinus Surgery Dental & Oral Surgery Neurosurgery Thoracic Surgery Plastic & Reconstructive Surgery
By End User
Hospitals Ambulatory Surgical Centers Specialty Surgical Centers Dental Clinics & Dental Surgery Centers Other End Users
By Region
North America Europe Asia-Pacific Middle East and Africa South America
Key Players
The market is highly fragmented, with global leaders alongside regional and emerging manufacturers. Companies profiled in the report include:
Global Surgical & Hemostat Leaders
Baxter International Inc. / Baxter Healthcare Ethicon / SURGICEL (Johnson & Johnson MedTech) B. Braun SE / B. Braun Melsungen AG Stryker Corporation Smith+Nephew plc CONMED Corporation Olympus Corporation Artivion, Inc. / CryoLife
Biosurgery, Biologics & Materials Specialists
Advanced Medical Solutions Group plc Anika Therapeutics, Inc. Marine Polymer Technologies, Inc. RESORBA Medical GmbH GELITA AG / Gelita Medical GmbH Ferrosan Medical Devices CSL Behring Grifols, S.A. Octapharma AG Kedrion S.p.A. LFB S.A. Takeda Pharmaceutical Company Limited Cohera Medical, Inc. Hemostat Laboratories AtriCure, Inc. Vascular Solutions, Inc. Vivostat A/S FzioMed, Inc. Genzyme Corporation / Sanofi S.A.
Regional & Emerging Manufacturers
Mizuho America, Inc. Kitotech Medical St. Jude Medical, LLC Zydus Lifesciences Limited HLL Lifecare Limited Meril Life Sciences Pvt. Ltd. Surgitech Innovation Vitrex Medical A/S HemCon Medical Technologies Qingdao Huaren Medical Product Co., Ltd. Shenzhen Lifotronic Technology Co., Ltd. Guangzhou Wego Biotechnology Co., Ltd. Shanghai Haohai Biological Technology Co., Ltd. Equimedical B.V. Medira Ltd. C.R. Bard, Inc. MBP GmbH NZMS Zhonghuishengxi Delta A Healthcare Curamedical GmbH Medprin Biotech GmbH Dilon Technologies France SAS Others
Table of Contents
1. Report Overview — Scope, Segment Analysis, Regulatory & Investment Scenario, Analysis by Product Type / Material / Surgical Application / End User
2. Drivers, Restraints, Challenges & Opportunities
3. Global Growth Trends — SWOT, PESTEL, Porter's Five Forces
4. Post-COVID-19 Analysis (V / U / L / W scenarios)
5. Companies Analysis — Rankings & Market Share
6. Executive Summary
7. Global Market Forecast by Region (2020–2040)
8. North America Analysis by Countries
9. Europe Analysis by Countries
10. Asia-Pacific Analysis by Countries
11. Middle East & Africa Analysis by Countries
12. Latin America Analysis by Countries
13–38. Company Profiles (Financials, Product Summary, Recent Developments)
39–40. Conclusion & Reference Links
41–42. Appendix — Methodology, Data Sources, Market Estimation & Scope
43. Expanded A–Z Operational, Production, Volume, Pricing & Competition Analysis
Report Snapshot
| Base Year |
2025 |
| Historical Period |
2020–2024 |
| Forecast Period |
2026–2040 |
| Market Value (2025) |
USD 2,958.89 Million |
| Market Value (2040) |
USD 7,577.70 Million |
| CAGR (2025–2040) |
6.47% |
| Units |
Value (USD Million) |
| Segments Covered |
Product Type, Material / Composition, Surgical Application, End User, Region |
Company Financial Sources
Source: Primary Research, Secondary Research, White Paper, Other Publications and Company Websites. Segment-level and company-level figures are presented as coverage/scope; specific value splits are quantified in the full report.
